{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:54:50Z","timestamp":1789696490034,"version":"4.0.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.mayocp.2011.10.001","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T17:34:38Z","timestamp":1326130478000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology"],"prefix":"10.1016","volume":"87","author":[{"given":"Michael W.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.mayocp.2011.10.001_bib1","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis","volume":"267","author":"Folkman","year":"1992","journal-title":"J Biol Chem"},{"issue":"6801","key":"10.1016\/j.mayocp.2011.10.001_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.mayocp.2011.10.001_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"4587","key":"10.1016\/j.mayocp.2011.10.001_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mayocp.2011.10.001_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"6573","key":"10.1016\/j.mayocp.2011.10.001_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"Gerber","year":"1999","journal-title":"Development"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI119416","article-title":"Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis","volume":"99","author":"Kitamoto","year":"1997","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicol Pathol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"Makinen","year":"2002","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2011.10.001_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0102-76382010000300006","article-title":"VEGF gene therapy for angiogenesis in refractory angina: phase I\/II clinical trial","volume":"25","author":"Kalil","year":"2010","journal-title":"Rev Bras Cir Cardiovasc"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","article-title":"Diabetic macular edema: pathogenesis and treatment","volume":"54","author":"Bhagat","year":"2009","journal-title":"Surv Ophthalmol"},{"issue":"36","key":"10.1016\/j.mayocp.2011.10.001_bib15","doi-asserted-by":"crossref","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","article-title":"Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms","volume":"267","author":"Houck","year":"1992","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib16","first-page":"519","article-title":"Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family","volume":"5","author":"Shibuya","year":"1990","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.mayocp.2011.10.001_bib17","first-page":"1677","article-title":"Identification of a new endothelial cell growth factor receptor tyrosine kinase","volume":"6","author":"Terman","year":"1991","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc2868","article-title":"Targeting the tumour vasculature: insights from physiological angiogenesis","volume":"10","author":"Chung","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib19","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1074\/jbc.273.4.2090","article-title":"Two functional forms of vascular endothelial growth factor receptor-2\/Flk-1 mRNA are expressed in normal rat retina","volume":"273","author":"Wen","year":"1998","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib20","doi-asserted-by":"crossref","first-page":"C1367","DOI":"10.1152\/ajpcell.2001.280.6.C1367","article-title":"Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis","volume":"280","author":"Dor","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2011.10.001_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0006-8993(02)03766-6","article-title":"Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina","volume":"969","author":"Famiglietti","year":"2003","journal-title":"Brain Res"},{"issue":"5-6","key":"10.1016\/j.mayocp.2011.10.001_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0006-2952(02)01168-1","article-title":"Signal transduction to hypoxia-inducible factor 1","volume":"64","author":"Semenza","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"issue":"6733","key":"10.1016\/j.mayocp.2011.10.001_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"4-5","key":"10.1016\/j.mayocp.2011.10.001_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semcdb.2005.03.001","article-title":"The HIF pathway in cancer","volume":"16","author":"Maxwell","year":"2005","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr Rev"},{"issue":"2 pt 2","key":"10.1016\/j.mayocp.2011.10.001_bib28","first-page":"H586","article-title":"Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries","volume":"265","author":"Ku","year":"1993","journal-title":"Am J Physiol"},{"issue":"2 pt 2","key":"10.1016\/j.mayocp.2011.10.001_bib29","first-page":"H687","article-title":"Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway","volume":"273","author":"Bates","year":"1997","journal-title":"Am J Physiol"},{"issue":"pt 6","key":"10.1016\/j.mayocp.2011.10.001_bib30","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1242\/jcs.108.6.2369","article-title":"Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor","volume":"108","author":"Roberts","year":"1995","journal-title":"J Cell Sci"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1096\/fasebj.9.10.7615160","article-title":"Endothelial cell-to-cell junctions","volume":"9","author":"Dejana","year":"1995","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/08820539909069543","article-title":"Molecular mechanisms of vascular permeability in diabetic retinopathy","volume":"14","author":"Antonetti","year":"1999","journal-title":"Sem Ophthalmol"},{"issue":"21","key":"10.1016\/j.mayocp.2011.10.001_bib33","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","article-title":"Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.mayocp.2011.10.001_bib34","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","article-title":"Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition","volume":"96","author":"Miyamoto","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.mayocp.2011.10.001_bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"issue":"24","key":"10.1016\/j.mayocp.2011.10.001_bib37","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.preteyeres.2010.09.003","article-title":"Metabolic physiology in age related macular degeneration","volume":"30","author":"Stefansson","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pneurobio.2011.05.011","article-title":"Age related macular degeneration and drusen: neuroinflammation in the retina","volume":"95","author":"Buschini","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.10.001_bib40","first-page":"855","article-title":"Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes","volume":"37","author":"Lopez","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"27","key":"10.1016\/j.mayocp.2011.10.001_bib41","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2011.10.001_bib42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bjo.2009.174946","article-title":"Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study","volume":"94","author":"Friberg","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.mayocp.2011.10.001_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0025-6196(11)60847-1","article-title":"Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration","volume":"83","author":"Diago","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib47","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ophtha.2010.01.056","article-title":"Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study","volume":"117","author":"Arevalo","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen","volume":"293","author":"Chen","year":"1999","journal-title":"J Mol Biol"},{"issue":"8","key":"10.1016\/j.mayocp.2011.10.001_bib49","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"14","key":"10.1016\/j.mayocp.2011.10.001_bib50","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2011.10.001_bib51","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2011.10.001_bib52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"10.1016\/j.mayocp.2011.10.001_bib53","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2011.10.001_bib54","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.mayocp.2011.10.001_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.mayocp.2011.10.001_bib56","first-page":"659","article-title":"Retinal capillary pericyte apoptosis in early human diabetic retinopathy","volume":"110","author":"Li","year":"1997","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.mayocp.2011.10.001_bib57","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib59","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.mayocp.2011.10.001_bib60","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.ophtha.2006.07.032","article-title":"Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy","volume":"113","author":"Aiello","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.mayocp.2011.10.001_bib62","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","article-title":"Retinal vein thrombosis: pathogenesis and management","volume":"8","author":"Rehak","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1016\/j.mayocp.2011.10.001_bib63","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib64","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.mayocp.2011.10.001_bib65","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.mayocp.2011.10.001_bib66","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions","volume":"94","author":"Figueroa","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib67","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/IAE.0b013e3181bcef53","article-title":"Comparison of two doses of intravitreal bevacizumab as the primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months","volume":"29","author":"Wu","year":"2009","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.mayocp.2011.10.001_bib68","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","article-title":"Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial","volume":"18","author":"Yazdani","year":"2009","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2011.10.001_bib70","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.mayocp.2011.10.001_bib71","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2011.10.001_bib72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0006-291X(91)91276-I","article-title":"Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells","volume":"181","author":"Pepper","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","article-title":"MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis","volume":"2","author":"Hiratsuka","year":"2002","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib74","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/138945006778559111","article-title":"The many antithrombotic actions of nitric oxide","volume":"7","author":"Tziros","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib75","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic vascular endothelial cells become procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib76","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm1428","article-title":"VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis","volume":"12","author":"Tam","year":"2006","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.mayocp.2011.10.001_bib77","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/bjs.6100","article-title":"Vascular endothelial growth factor is associated with histological instability of carotid plaques","volume":"95","author":"Russell","year":"2008","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib78","first-page":"161","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy","volume":"31","author":"Qian","year":"2011","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.mayocp.2011.10.001_bib79","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","article-title":"Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab","volume":"94","author":"Matsuyama","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib80","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/IAE.0b013e3181ed8c80","article-title":"Bilateral intravitreal injection of antivascular endothelial growth factor therapy","volume":"31","author":"Mahajan","year":"2011","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.mayocp.2011.10.001_bib82","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib83","first-page":"748","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"356","author":"Gillies","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2011.10.001_bib84","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.mayocp.2011.10.001_bib85","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.10.001_bib86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safely of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.10.001_bib87","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.mayocp.2011.10.001_bib88","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","article-title":"Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice","volume":"8","author":"Compernolle","year":"2002","journal-title":"Nat Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:06:02Z","timestamp":1710457562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0025619611000073"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.10.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}